The North America chronic inflammatory demyelinating polyneuropathy therapeutics market was valued at USD 775.83 Million in 2025 and is expected to grow at a CAGR of 6.60%, reaching USD 1470.07 Million by 2035. The market is experiencing growth due to increasing diagnostic rates and adoption of novel therapeutics in the region.
Base Year
Historical Period
Forecast Period
Pharmaceutical companies in North America are actively investing in the research and development of new treatments for CIDP, resulting in increased market growth.
The rise in approvals of novel therapies by health regulatory authorities such as the FDA is one of the major market trends.
The market share is influenced by the rising advancements in personalized medicine and the growing demand for targeted therapies.
Compound Annual Growth Rate
6.6%
Value in USD Million
2026-2035
*this image is indicative*
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable autoimmune disorder, with around 80% of people responding to one or more of the available treatments. Intravenous and subcutaneous immunoglobulins, corticosteroids, and plasma exchanges are the first-line evidence-based therapies for the autoimmune disorder. In cases of refractoriness or perceived overdependence on first-line therapies, cyclophosphamide, rituximab, and mycophenolate mofetil are commonly used. Pharmaceutical companies in North America are actively investing in the research and development of new treatments for CIDP, which is driving innovation in the global chronic inflammatory demyelinating polyneuropathy therapeutics market. Further, the rising advancements in personalized medicine and the growing demand for targeted therapies are expected to propel the North America chronic inflammatory demyelinating polyneuropathy therapeutics market growth.
Chronic inflammatory demyelinating polyneuropathy can lead to symptoms such as symmetric weakness or loss of feeling in the arms and legs. One-third of patients with CIDP will need a wheelchair if proper treatment is not given which indicates the need for potent treatments. In April 2024, a global immunology company argenx SE announced a potential US Food and Drug Administration (FDA) approval and launch plans for a subcutaneous version of its leading asset, Vyvgart Hytrulo, to treat chronic inflammatory demyelinating polyneuropathy. The company revealed positive data from its late stage ADHERE trial that showed rapid clinical improvement and reduced risk of relapse of CIDP patients who took Vyvgart. Around 67% of participants responded to the drug and 81% experienced at least one point of improvement over baseline on their Treatment disability scores and Inflammatory Neuropathy Cause. The increased development of such safe and effective medications is poised to boost the North America chronic inflammatory demyelinating polyneuropathy therapeutics market demand in the forecast period.
The rise in approvals of novel therapeutics by health regulatory authorities is one of the major market trends. In January 2024, global biopharmaceutical company Takeda Pharmaceuticals received FDA approval for its subcutaneous immunoglobin (SCIG) infusion HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patients. The approval is based on the Phase 3 ADVANCE-CIDP 1 study that demonstrated HYQVIA superiority over placebo in preventing CIDP relapse. Thus, the presence of a supportive regulatory system is anticipated to expedite the market entry of new and advanced therapeutics, which will ultimately bolster the market growth.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
The key features of the market report include funding and investment analysis, and partnerships and collaborations analysis by the leading key players. The major companies in the market are as follows:
This United States-based biopharmaceutical company, specializing in manufacturing plasma-derived and recombination therapeutic products, is known for its liquid IgG product Hizentra indicated for the treatment of chronic inflammatory demyelinating polyneuropathy.
Grifols, S.A., a multinational pharmaceutical and chemical manufacturer, is a leading provider of blood plasma-based products. The company sells its intravenous immunoglobulin (IVIG) under the brands Flebogamma® and Gamunex® for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the United States and Canada.
Shire plc, a UK-founded Jersey-registered specialty biopharmaceutical company, is focused on developing treatments for rare diseases. In 2019, it was acquired by Takeda Pharmaceuticals.
This Switzerland-based pharmaceutical company is one of the largest providers of high-quality human proteins from human plasma and human cell lines. It has a robust immunoglobulin product portfolio for patients requiring IgG immunotherapy.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Biogen Idec, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sanofi, and Roche Holding AG.
North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Companies
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The North America chronic inflammatory demyelinating polyneuropathy therapeutics market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.60% during the forecast period of 2026-2035.
The rising advancements in personalized medicine and heightened patient awareness are fuelling the demand for the market.
One of the significant trends in the market is the rise in approvals of novel therapeutics by health regulatory authorities. In January 2024, Takeda Pharmaceuticals received FDA approval for its subcutaneous immunoglobin (SCIG) infusion HYQVIA as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patients.
Based on the drug type, the market is segmented into corticosteroids, and immunoglobulin, among others.
By route of administration, the market is divided into oral and injectable.
Major distribution channels of the market include hospital pharmacies, retail pharmacies, and online pharmacies.
The market segmentation by countries includes the United States and Canada.
The key players in the market are CSL Behring, Grifols, S.A., Shire, Octapharma AG, Biogen Idec, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sanofi, and Roche Holding AG.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share